Join MAPS on LinkedIn to further build your professional connections within Medical Affairs through our Company and Group Pages.
Follow us on Twitter and say abreast of MAPS activities and key issues for Medical Affairs professionals.
Former VP, Head of US Medical Affairs
Dr. Richardson has a 20-year record in optimizing product life cycle through medical brand strategy,
communications and relationship management with healthcare providers, payors, and other medically
focused stakeholders. She has success in building and expanding medical teams in specialty and rare
disease brands to generate and disseminate evidence demonstrating product value.
Most recently, Dr. Richardson served as Vice President, Head of US Medical Affairs at Shire in June 2016-
2017 were she led teams for seven therapeutic areas including the Field Medical Teams and Medical
Outcomes Liaisons Team. From 2013-1015 she was Regional Head of North America at Baxter/Baxalta
aligned medical strategy and communication across hematology portfolio (ADVATE, FEIBA, RIXUBIS).
Under her leadership, the medical teams launched OBIZUR, ADYNOVATE and Vonvendi. She
generated a new Patient Reported Outcome (PRO) tool, Goal Attainment Scaling (GAS), demonstrating
personally and clinically meaningful changes in people with hemophilia.
Prior to Baxter, Dr. Richardson spent 16 years at Eisai Inc (1995-2011) were she held progressively
increasing roles with responsibility and accountability and served as VP, Medical Affairs, Primary Care and
Specialty Business Unit. She led the medical affairs strategy for Aricept, the most prescribed drug for
Alzheimer’s disease, Aciphex for heartburn, and Banzel for epilepsy. Dr Richardson co-chaired the
Medical Subcommittee for Aricept and led numerous phase lV clinical trials in Early Alzheimer’s disease,
Mild Cognitive Impairment (MCI), Down Syndrome, and other patient populations. She also led the
clinical trial for Aricept in severe Alzheimer’s disease patients that broaden the FDA and a cross-functional
oncology submission team that completed the supplemental biological license application (sBLA) and
achieved full FDA approval for ONTAK. Dr. Richardson partnered with the business development team
that successfully led to a Eisai’s portfolio expansion in epilepsy and oncology.
Dr. Richardson received her bachelor of science degree in Pathobiology from the University of
Connecticut, Storrs, CT and her PhD degree in Pharmacology from Howard University in Washington,
DC. She completed a post-doctoral fellowship in Neuroscience at the University of Pennsylvania in